A Phase 3 interventional study of Placebo and AG-348 in Pyruvate Kinase Deficiency and Anemia, Hemolytic, sponsored by Agios Pharmaceuticals, Inc.. Completed at 46 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-24.
Sponsored by Agios Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Anemia, Hemolytic with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Anemia, Hemolytic · United States.
Among the 35 studies in Anemia, Hemolytic with a site in United States, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 18th registered.
56 studies on the registry are indexed under Anemia, Hemolytic; 16 are open to participants now.
Browse Anemia, Hemolytic studies →8 of the 35 studies in Anemia, Hemolytic with a site in United States are open now. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–90
International PNH Interest Group · Sites in United States
Apellis Pharmaceuticals, Inc. · Sites in United States, Czechia, France and 6 more countries
Ages 12–17
Children's Hospital Medical Center, Cincinnati · Sites in United States
Insel Gruppe AG, University Hospital Bern · Sites in United States, Austria, Czechia and 4 more countries
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Anemia, Hemolytic studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 4 · Phase 4 3
First in 1997; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 48 across 39 interventional studies indexed under Anemia, Hemolytic.
Median enrollment 47 across the 26 interventional studies, 254 across the 9 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 35 have an industry lead sponsor. The 10 most frequent:
Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Agios Pharmaceuticals, Inc. has 5 studies filed under Anemia, Hemolytic — fewer than ten, so there is no comparison to draw.
2 of the studies in Anemia, Hemolytic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07566494National Heart, Lung, and Blood Institute (NHLBI)Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease | 2027-04-27 |
| NCT07612345University of UtahHigh-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study | 2027-07-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Anemia, Hemolytic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study AG348-C-006 evaluated the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase (PK) deficiency, who were not regularly receiving blood transfusions. Participants were randomized 1:1 to receive either AG-348 or a matching placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a matching placebo to AG-348 tablets, for a period of 12 weeks as an optimized dose. This was followed by matching placebo further, for a period of 12 weeks as a fixed-dose.
Drug: Placebo
Participants received AG-348 tablets, 5 milligrams (mg) twice daily (BID), administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 5 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
Drug: AG-348
Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 20 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
Drug: AG-348
Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 50 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
Drug: AG-348
Placebo matching AG-348 tablets, administered to maintain the blind.
AG-348 tablets.
Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR)
Hemoglobin response (HR) is defined as a ≥1.5 g/dL (0.93 mmol/L) increase in Hb concentration from baseline that is sustained at 2 or more scheduled assessments at Weeks 16, 20, and 24. The baseline Hb concentration is the average of all available Hb concentrations for a participant during the Screening Period up to the first dose of study treatment. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, Weeks 16, 20, 24
Average Change From Baseline in Hb Concentration at Weeks 16, 20 and 24
This is the change in Hb concentration at Weeks 16, 20 and 24 compared to baseline. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, Weeks 16, 20, 24
Maximum Change From Baseline in Hb Concentration
This is the maximum change from baseline in Hb concentration up to Week 24. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, up to Week 24
Time to Achieve an Increase in Hb Concentration of 1.5 g/dL or More
This is the time taken to first achieve an increase of hemoglobin concentration of 1.5 g/dL or more from baseline. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, up to Week 24
Average Change From Baseline in Indirect Bilirubin at Weeks 16, 20 and 24
The change from baseline in indirect bilirubin levels was summarized. Indirect bilirubin is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, Weeks 16, 20, 24
Average Change From Baseline in Lactic Acid Dehydrogenase (LDH) at Weeks 16, 20 and 24
The change from baseline in LDH levels was summarized. LDH is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, Weeks 16, 20, 24
Average Change From Baseline in Haptoglobin at Weeks 16, 20 and 24
The change from baseline in haptoglobin levels was summarized. Haptoglobin levels are markers for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, Weeks 16, 20, 24
Average Change From Baseline in Reticulocyte Percentages at Weeks 16, 20 and 24
The change from baseline in reticulocyte percentage was summarized. Reticulocyte levels are markers for hematopoietic activity. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, Weeks 16, 20, 24
Change From Baseline in Pyruvate Kinase Deficiency Diary (PKDD) Score at Week 24
The PKDD is a 7-item patient reported outcome (PRO) measure of the core signs and symptoms associated with PK deficiency in adults. Participants rate their experience with symptoms of PK deficiency on the present day. The symptoms include those associated with tiredness, jaundice, bone pain, shortness of breath, and energy level. The score ranges from 25 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDD weekly scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, Week 24
Change From Baseline in Pyruvate Kinase Deficiency Impact Assessment (PKDIA) Score at Week 24
The PKDIA is a 12-item patient reported outcome (PRO) measure of the common impacts of PK deficiency on activities of daily living. Participants rate how PK deficiency has impacted aspects of daily living in the past 7 days, including impacts on relationships; perceived appearance; work performance; and leisure, social, mental, and physical activities. The score range is 30 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDIA scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
Time frame: Baseline, Week 24
Percentage of Participants With Adverse Events
An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: From signing of informed consent form to the end of study, including follow-up (up to Day 197)
Area Under the Curve From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] for AG-348 at Week 12
Time frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)
Maximum Plasma Concentration (Cmax) for AG-348
Time frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)
Time to Cmax (Tmax) for AG-348
Time frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)
Time to Last Measurable Concentration (Tlast) for AG-348
Time frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)
Exposure-Response Relationship of Adverse Event (Hot Flush) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters
Predicted probability of experiencing all grade hot flush at the doses of 5, 20, and 50 mg mitapivat BID based on exposure-response model.
Time frame: From first dose of mitapivat to the end of study, including follow-up (up to Day 197)
Exposure-Response Relationship Between Safety Parameters (Sex Hormone in Male Subjects) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters
Predicted percent change from baseline at Week 24 in the sex hormone measures (total testosterone, free testosterone, and estrone) at the doses of 5, 20, and 50 mg mitapivat BID in male participants.
Time frame: Baseline, Week 24
Percentage of Participants With Adverse Events of Special Interest (AESI)
An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.
Time frame: Through 4 weeks after last dose (approximately Week 31)
Change From Baseline in Bone Mineral Density Z-Score at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Bone Mineral Density T-Score at Week 24
Time frame: Baseline, Week 24
A total of 80 participants were randomized in the study, which was conducted across multiple sites in 14 countries: Brazil, Canada, Denmark, France, Germany, Italy, Japan, Republic of Korea, Netherlands, Spain, Switzerland, Turkey, United Kingdom, and United States. The study was conducted from 9 August 2018 to 9 October 2020.
| Milestone | Placebo Comparator: Placebo | Experimental: AG-348 5 mg | Experimental: AG-348, 20 mg | Experimental: AG-348, 50 mg |
|---|---|---|---|---|
| Started | 40 | 2 | 3 | 35 |
| Completed | 39 | 2 | 3 | 35 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
Hemoglobin response (HR) is defined as a ≥1.5 g/dL (0.93 mmol/L) increase in Hb concentration from baseline that is sustained at 2 or more scheduled assessments at Weeks 16, 20, and 24. The baseline Hb concentration is the average of all available Hb concentrations for a participant during the Screening Period up to the first dose of study treatment. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| percentage of participants | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR) | 0 | 40.0 |
This is the change in Hb concentration at Weeks 16, 20 and 24 compared to baseline. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| grams per liter (g/L) | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Average Change From Baseline in Hb Concentration at Weeks 16, 20 and 24 | -1.48 ± 2.082 | 16.73 ± 2.075 |
This is the maximum change from baseline in Hb concentration up to Week 24. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| g/L | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Maximum Change From Baseline in Hb Concentration | 4.76 ± 4.217 | 23.94 ± 21.367 |
This is the time taken to first achieve an increase of hemoglobin concentration of 1.5 g/dL or more from baseline. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| weeks | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Time to Achieve an Increase in Hb Concentration of 1.5 g/dL or More | — | 7.66 ± 4.050 |
The change from baseline in indirect bilirubin levels was summarized. Indirect bilirubin is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| micromoles per liter (μmol/L) | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Average Change From Baseline in Indirect Bilirubin at Weeks 16, 20 and 24 | 5.10 ± 4.061 | -21.16 ± 4.228 |
The change from baseline in LDH levels was summarized. LDH is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| units per litre (U/L) | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Average Change From Baseline in Lactic Acid Dehydrogenase (LDH) at Weeks 16, 20 and 24 | -21.18 ± 16.040 | -91.99 ± 16.222 |
The change from baseline in haptoglobin levels was summarized. Haptoglobin levels are markers for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| g/L | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Average Change From Baseline in Haptoglobin at Weeks 16, 20 and 24 | 0.012 ± 0.0412 | 0.169 ± 0.0408 |
The change from baseline in reticulocyte percentage was summarized. Reticulocyte levels are markers for hematopoietic activity. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| Reticulocyte percentages | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Average Change From Baseline in Reticulocyte Percentages at Weeks 16, 20 and 24 | 0.0038 ± 0.01390 | -0.0973 ± 0.01401 |
The PKDD is a 7-item patient reported outcome (PRO) measure of the core signs and symptoms associated with PK deficiency in adults. Participants rate their experience with symptoms of PK deficiency on the present day. The symptoms include those associated with tiredness, jaundice, bone pain, shortness of breath, and energy level. The score ranges from 25 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDD weekly scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| score on a scale | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Change From Baseline in Pyruvate Kinase Deficiency Diary (PKDD) Score at Week 24 | -2.05 ± 0.976 | -5.16 ± 0.955 |
The PKDIA is a 12-item patient reported outcome (PRO) measure of the common impacts of PK deficiency on activities of daily living. Participants rate how PK deficiency has impacted aspects of daily living in the past 7 days, including impacts on relationships; perceived appearance; work performance; and leisure, social, mental, and physical activities. The score range is 30 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDIA scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).
| score on a scale | Placebo Comparator: Placebo | Experimental: AG-348 |
|---|---|---|
| Change From Baseline in Pyruvate Kinase Deficiency Impact Assessment (PKDIA) Score at Week 24 | -1.39 ± 1.157 | -4.65 ± 1.123 |
An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| percentage of participants | Placebo Comparator: Placebo | Experimental: AG-348 5 mg | Experimental: AG-348 20 mg | Experimental: AG-348 50 mg |
|---|---|---|---|---|
| Percentage of Participants With Adverse Events | 89.7 | 50.0 | 100 | 88.6 |
| h*ng/mL | AG-348, 5mg | AG-348, 20 mg | AG-348, 50mg |
|---|---|---|---|
| Area Under the Curve From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] for AG-348 at Week 12 | 565.9 ± NA | 1481.2 ± 26.9 | 2973.3 ± 35.6 |
| Nanograms per milliliter (ng/mL) | AG-348, 5mg | AG-348, 20 mg | AG-348, 50mg |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) for AG-348 | 156.9 ± NA | 373.1 ± 13.6 | 1033 ± 31.2 |
| hours (h) | AG-348, 5mg | AG-348, 20mg | AG-348, 50mg |
|---|---|---|---|
| Time to Cmax (Tmax) for AG-348 | 0.75 (0.50 to 1.00) | 1.02 (0.92 to 2.17) | 0.50 (0.42 to 1.92) |
| hours (h) | AG-348, 5mg | AG-348, 20mg | AG-346, 50mg |
|---|---|---|---|
| Time to Last Measurable Concentration (Tlast) for AG-348 | 7.787 ± NA | 7.809 ± 4.2 | 7.162 ± 28.0 |
Predicted probability of experiencing all grade hot flush at the doses of 5, 20, and 50 mg mitapivat BID based on exposure-response model.
| Percent probability | Experimental: AG-348 5 mg | Experimental: AG-348 20 mg | Experimental: AG-348 50 mg |
|---|---|---|---|
| Exposure-Response Relationship of Adverse Event (Hot Flush) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters | 3.37 (1.22 to 7.35) | 4.03 (1.61 to 8.36) | 5.5 (2.48 to 10.5) |
An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Predicted percent change from baseline at Week 24 in the sex hormone measures (total testosterone, free testosterone, and estrone) at the doses of 5, 20, and 50 mg mitapivat BID in male participants.
| Percent change | Experimental: AG-348 5 mg | Experimental: AG-348 20 mg | Experimental: AG-348 50 mg |
|---|---|---|---|
| Total Testosterone | 0.877 (0.41 to 1.43) | 3.18 (1.49 to 5.4) | 7.59 (3.29 to 13.7) |
| Free Testosterone | 6.01 (1.66 to 13.2) | 14.1 (4 to 27.5) | 26 (7.14 to 55.1) |
| Estrone | -31.5 (-51 to -21.1) | -56.5 (-67.3 to -48.4) | -68.2 (-74.5 to -62.6) |
Collected over From time of signing of informed consent form to end of study, including follow-up (up to Day 197). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Comparator: Placebo | 0/39 (0%) | 2/39 (5.1%) | 35/39 (89.7%) |
| Experimental: AG-348, 5 mg | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Experimental: AG-348, 20 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Experimental: AG-348, 50 mg | 0/35 (0%) | 3/35 (8.6%) | 31/35 (88.6%) |
| Event | Placebo Comparator: Placebo | Experimental: AG-348, 5 mg | Experimental: AG-348, 20 mg | Experimental: AG-348, 50 mg |
|---|---|---|---|---|
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/39 | 0/2 | 1/3 | 0/35 |
| GastroenteritisInfections and infestations | 0/39 | 0/2 | 0/3 | 1/35 |
| Atrial fibrillationCardiac disorders | 0/39 | 0/2 | 0/3 | 1/35 |
| Rib fractureInjury, poisoning and procedural complications | 0/39 | 0/2 | 0/3 | 1/35 |
| Metapneumovirus infectionInfections and infestations | 1/39 | 0/2 | 0/3 | 0/35 |
| Obstructive pancreatitisGastrointestinal disorders | 1/39 | 0/2 | 0/3 | 0/35 |
| Event | Placebo Comparator: Placebo | Experimental: AG-348, 5 mg | Experimental: AG-348, 20 mg | Experimental: AG-348, 50 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 9/39 | 0/2 | 2/3 | 5/35 |
| DiarrhoeaGastrointestinal disorders | 7/39 | 0/2 | 2/3 | 2/35 |
| NasopharyngitisInfections and infestations | 6/39 | 0/2 | 2/3 | 3/35 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/39 | 0/2 | 2/3 | 2/35 |
| GastroenteritisInfections and infestations | 0/39 | 1/2 | 0/3 | 2/35 |
| DyspepsiaGastrointestinal disorders | 2/39 | 0/2 | 1/3 | 0/35 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/39 | 0/2 | 1/3 | 2/35 |
| FatigueGeneral disorders | 4/39 | 0/2 | 1/3 | 4/35 |
| HeadacheNervous system disorders | 13/39 | 0/2 | 1/3 | 5/35 |
| HypertensionVascular disorders | 0/39 | 0/2 | 1/3 | 1/35 |
Full analysis set included all participants who were randomized.
| Age, Continuous(years) | Placebo Comparator: Placebo | Experimental: AG-348, 5 mg | Experimental: AG-348, 20 mg | Experimental: AG-348, 50 mg | Total |
|---|---|---|---|---|---|
| Mean | 37.2 ± 15.92 | 21.5 ± 4.95 | 48.0 ± 26.21 | 35.8 ± 14.07 | 36.6 ± 15.47 |
| Sex: Female, Male(Participants) | Placebo Comparator: Placebo | Experimental: AG-348, 5 mg | Experimental: AG-348, 20 mg | Experimental: AG-348, 50 mg | Total |
|---|---|---|---|---|---|
| Female | 24 | 0 | 2 | 22 | 48 |
| Male | 16 | 2 | 1 | 13 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Comparator: Placebo | Experimental: AG-348, 5 mg | Experimental: AG-348, 20 mg | Experimental: AG-348, 50 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 2 | 3 |
| Not Hispanic or Latino | 34 | 1 | 2 | 25 | 62 |
| Unknown or Not Reported | 5 | 1 | 1 | 8 | 15 |
| Race (NIH/OMB)(Participants) | Placebo Comparator: Placebo | Experimental: AG-348, 5 mg | Experimental: AG-348, 20 mg | Experimental: AG-348, 50 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 0 | 0 | 5 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 32 | 2 | 3 | 23 | 60 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 4 | 0 | 0 | 6 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Oct 2020, 26 months.
Results were first posted in May 2022, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitapivat